New clinical trials recently added to the National Cancer Institute’s database

**BRAIN/CNS TUMORS**

Light Sedation or Intubated General Anesthesia in Reducing Complications and Length of Hospital Stay in Patients With Brain Cancer Undergoing Craniotomy

- **Phase:** Phase IV  
- **Type:** Supportive care, Treatment  
- **Age:** Over 18  
- **Trial IDs:** OSU-12161, NCI-2014-01110, 2014C0007, NCT02193568

**BREAST CANCER**

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)

- **Phase:** Phase I  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** E7389-M001-218, NCI-2015-01436, KEYNOTE-150, NCT02513472

Hypofractionated Regional Nodal Radiation Therapy in Treating Older Patients with Breast Cancer Who Have Undergone Surgery

- **Phase:** Phase II  
- **Type:** Biomarker/Laboratory analysis, Treatment  
- **Age:** 50 and over  
- **Trial IDs:** MCC-15-10994, NCI-2015-01317, NCT02515110

Panitumumab, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Carboplatin in Treating Patients with HER2-Negative Primary Inflammatory Breast Cancer Receiving Combination Chemotherapy and Surgery

- **Phase:** Phase II  
- **Type:** Biomarker/Laboratory analysis, Treatment  
- **Age:** 18 and over  
- **Trial IDs:** A5481044, NCI-2015-00706, NCT02420795

Metformin Hydrochloride in Reducing Treatment-Related Neuropathy in Patients with Stage I-IV Breast Cancer Undergoing Treatment with Paclitaxel

- **Phase:** Phase II  
- **Type:** Supportive care  
- **Age:** Over 18  
- **Trial IDs:** 2014-0438, NCI-2015-00510, NCT02360059

Carboplatin and Docetaxel or Carboplatin and Paclitaxel Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with Stage I-III Triple-Negative Breast Cancer

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 to 70  
- **Trial IDs:** 2014-BRST-TNBC-LQT, NCI-2015-01416, STUDY00002467, NCT02413320

**CERVICAL CANCER**

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Stage IVB or Recurrent Cervical Cancer

- **Phase:** Phase II  
- **Type:** Biomarker/Laboratory analysis, Treatment  
- **Age:** 18 and over  
- **Trial IDs:** 2014-0625, NCI-2015-00211, NCT02348398

**COLORECTAL CANCER**

A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE)

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** BP29262, NCI-2014-01282, NCT02391545

Azacitidine in Measuring Tumor Response in Patients with HPV Positive or Negative Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** 1404013771, NCI-2015-01437, 200 FR. 4 (2012-1), NCT02499120

**ENDOMETRIAL CANCER**

Levonorgestrel-Releasing Intradermal System with or without Everolimus in Treating Patients with Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

- **Phase:** Phase II  
- **Type:** Biomarker/Laboratory analysis, Treatment  
- **Age:** 18 and over  
- **Trial IDs:** 2014-0944, NCI-2015-00919, NCT02397083

**HEAD & NECK/ORAL CANCER**

Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity

- **Phase:** Phase II  
- **Type:** Biomarker/Laboratory analysis, Treatment  
- **Age:** 18 and over  
- **Trial IDs:** 2016153, NCI-2014-00756, NCT02119728

Surgery with or without Stereotactic Body Radiotherapy in Treating Patients with Previously-Irradiated Head and Neck Cancer

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** 2014-0630, NCI-2015-00521, NCT02420717

Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** IPI-145-19, NCI-2015-01462, NCT02391545

**LEUKEMIA/LYMPHOMA/MDS**

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** OSU-12161, NCI-2014-00706, NCT02509546

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** C34002, NCI-2015-00064, U1111-1163-2185, NCT02323113

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

- **Phase:** Phase II  
- **Type:** Biomarker/Laboratory analysis, Treatment  
- **Age:** 18 and over  
- **Trial IDs:** 2014-0625, NCI-2015-00779, NCT02420717

Akt/ERK Inhibitor ONC201 in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, or Transformed Large Cell Lymphoma

- **Phase:** Phase II  
- **Type:** Treatment  
- **Age:** 18 and over  
- **Trial IDs:** SGN35-016, NCI-2015-00706, NCT02420795
PROTOCOL ALERT
Continued from page 14

Leukemia (AML) Ineligible for Intensive Chemotherapy
Phase: Phase II
Type: Treatment
Age: 65 and over
Trial IDs: CR107273, NCI-2015-01326, 56022473AM2L002, NCT02472145
Meloxicam and Filgrastim in Collecting Peripheral Blood Stem Cells for Transplant in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 73
Trial IDs: IUCRCR-0419, NCI-2014-00470, NCT02078102

Augmented Berlin-Frankfurt-Munster Therapy and Ofatumumab in Treating Patients with B-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: 12 to 30
Bendamustine Hydrochloride, Obinutuzumab, and Dexamethasone in Treating Older Patients with Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 70 and over
Trial IDs: IRB14-1120, NCI-2015-00355, NCT02420210
Pembrolizumab in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCI1485, NCI-2014-02561, M014-005666-04, NCT02332980
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SCR1 CNS 20, NCI-2015-01335, NCT02113007
Rituximab and Pembrolizumab in Treating Patients with Relapsed Follicular Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
FLT PET/CT in Measuring Response in Patients with Previously Untreated Acute Myeloid Leukemia
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: EAY141, NCI-2015-00328, NCT02392429
Donor Hematopoietic Stem Cell Transplant and Combination Chemotherapy as Initial Salvage Therapy in Treating Patients with Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy
Phase: Phase II
Type: Treatment
Age: 18 to 60
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CCTL019C2201, NCI-2015-01461, 2014-00360-20, NCT02445248
LUNG CANCER
Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients with Recurrent or Metastatic Non-small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-80, NCI-2015-01411, 9878, NCT02535338
Selinexor and Docaetaxel in Treating Patients with Recurrent or Metastatic Squamous Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OAU-1452, NCI-2015-01165, NCT02536645
Study Evaluating the Efficacy, Safety and Pharmacokinetics in Patient With T790M-positive Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: HM-EMSI-202, NCI-2015-01440, NCT02485652
MELANOMA
Interleukin-12 Gene Electroporation Therapy and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CC #15852, NCI-2015-01300, 133438, 158532, NCT02493361
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients with Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0922, NCI-2015-01395, NCT02500576
MYELOMA
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Part 1: Treatment
Part 2: Supportive care
Part 3: Treatment
Part 4: Supportive care
At 32 pages, Part 4 is continued on page 16

To Reach OT:

- Editorial, Permissions, or Publishing Matters:
  Oncology Times
  333 Seventh Ave. 19th Fl.
  New York, NY 10001
  OT@LWWNY.com

- Advertising Sales:
  Brian Parker
  Wolters Kluwer Health Learning, Research & Practice
  Two Commerce Square
  2001 Market Street
  Philadelphia, PA 19103
  215-521-8969;
  brian.parker@wolterskluwer.com

- Classified Advertising:
  Joe Anzuena National Account Manager
  Wolters Kluwer Health
  Two Commerce Square
  2001 Market Street Philadelphia, PA 19103
  215-521-8532
  fax 215-701-2410
  Joe.Aнуenza@wolterskluwer.com

- Circulation Matters:
  Call 800-430-5450 or email OT@dmdconnects.com for quickest service, include account number, located above your name on the mailing label.

- Reprints:
  Bridget Quinn
  215-521-8807; fax: 215-405-3812
  bridgequin651@gmail.com
### Protocol Alert
Continued from page 15

<table>
<thead>
<tr>
<th>Age: 18 and over</th>
<th>Type: Treatment</th>
<th>Phase: Phase II, Phase I</th>
<th>Can not be removed by surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANCREATIC CANCER</td>
<td>Tosedostat and Capecitabine in treating patients with pancreatic cancer that is advanced, metastatic, or cannot be removed by surgery</td>
<td>Phase: Phase II, Phase I</td>
<td>Treatment Age: 18 and over</td>
</tr>
<tr>
<td>PROSTATE CANCER</td>
<td>Effects of endocrine therapy with or without Trametinib or Dasatinib in patients with localized, untreated prostate cancer undergoing surgery</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
</tr>
<tr>
<td>OVARIAN CANCER</td>
<td>Chemoimmunotherapy and vaccine therapy in treating patients with recurrent ovarian cancer</td>
<td>Phase: Phase II, Phase I</td>
<td>Treatment Age: 18 and over</td>
</tr>
<tr>
<td>MEDI4736 and Olaparib or Cediranib Maleate in treating patients with advanced solid tumors or recurrent ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
<td>Clinical Identifier: NCT02484404</td>
</tr>
<tr>
<td>Pembrolizumab in platinum resistant ovarian cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
<td>Clinical Identifier: NCT02432378</td>
</tr>
<tr>
<td>Cediranib Maleate in treating resistant ovarian cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
<td>Clinical Identifier: NCT02432378</td>
</tr>
<tr>
<td>Pembrolizumab in platinum resistant ovarian cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
<td>Clinical Identifier: NCT02432378</td>
</tr>
<tr>
<td>MOCUS CANCER</td>
<td>Efficacy and safety study of PBI-052404 in patients with stage IV metastatic pancreatic adenocarcinoma</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
</tr>
<tr>
<td>Clinical Identifier: NCT02352831</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD34-positive donor stem cell boost in improving graft function in patients who have undergone stem cell transplant</td>
<td>Phase: No phase specified</td>
<td>Treatment Age: Not specified</td>
<td>Clinical Identifier: NCT02439804</td>
</tr>
<tr>
<td>PROSTATE CANCER</td>
<td>Pembrolizumab in treating prostate cancer before undergoing surgery</td>
<td>Phase: Phase II</td>
<td>Treatment Age: Not specified</td>
</tr>
<tr>
<td>Clinical Identifier: NCT02329717</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDI4736 and Olaparib or Cediranib Maleate in treating patients with advanced solid tumors or recurrent ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
<td>Clinical Identifier: NCT02434560</td>
</tr>
<tr>
<td>REGORafenib and Gemcitabine Hydrochloride as Second-line Therapy in treating patients with metastatic pancreatic cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 to 75</td>
<td>Clinical Identifier: NCT02439804</td>
</tr>
<tr>
<td>Clinical Identifier: NCT02439804</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROSTATE CANCER</td>
<td>Regorafenib and Gemcitabine Hydrochloride as Second-line Therapy in Treating Patients with Metastatic Pancreatic Cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
</tr>
<tr>
<td>Clinical Identifier: NCT02383433</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOVEL CANCER</td>
<td>Pembrolizumab in treating patients with localized, untreated prostate cancer undergoing surgery</td>
<td>Phase: Phase II</td>
<td>Treatment Age: Not specified</td>
</tr>
<tr>
<td>Clinical Identifier: NCT02439804</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROSTATE CANCER</td>
<td>Pembrolizumab in platinum resistant ovarian cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: Not specified</td>
</tr>
<tr>
<td>Clinical Identifier: NCT02439804</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEDI4736 and Olaparib or Cediranib Maleate in treating patients with advanced solid tumors or recurrent ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: 18 and over</td>
<td>Clinical Identifier: NCT02434560</td>
</tr>
<tr>
<td>PROSTATE CANCER</td>
<td>Pembrolizumab in platinum resistant ovarian cancer</td>
<td>Phase: Phase II</td>
<td>Treatment Age: Not specified</td>
</tr>
<tr>
<td>Clinical Identifier: NCT02439804</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**OT on Your iPad—Easier Reading, Bonus Features!**

**bit.ly/OT-ipadApp**
PROTOCOL ALERT
Continued from page 16
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: 14238, NCI-2014-02079, NCT01428176, 116082, 14206, 14238/117640, NCT02939594

Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin C Followed by Standard Chemotherapy in Treating Patients With Peritoneal Carcinomatosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-09-332, NCI-2013-01214, 11-075, NCT02040142

Dendritic Cell Vaccine, Recombinant Interferon Alfa, Rintatolimod, and Celecoxib After Surgery in Treating Patients with Peritoneal Surface Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 12-110, NCI-2014-01357, 02151448, NCT02151448

Dexmedetomidine Hydrochloride in Reducing Pain in Patients Undergoing Thoracic Surgery
Phase: Phase III
Type: Supportive care
Age: 21 and over
Trial IDs: 13-163, NCI-2013-02150, NCT01973452

Eltrombopag Olanime in Increasing Platelet Counts in Patients Undergoing Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 2012-0920, NCI-2013-02348, NCT01927731

Endoscopic Dilation With or Without Triamcinolone in Treating Patients With Anastomotic or Radiation Induced Difficulty Swallowing
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: MGC 17316, NCI-2013-01370, 13.05.0023, NCT01873573

Endoscopic Radiofrequency Ablation in Treating Patients With Malignant Biliary Obstruction
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 11-405, NCI-2012-00258, NCT01543607

Donor Cytomegalovirus-Specific Cytotoxic T Lymphocytes in Treating Patients Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00013947, NCI-2013-00579, NCT01274377

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients with a Persistent Cytomegalovirus Infection after Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2013-0637, NCI-2014-01990, NCT02210078

Donor Cytotoxic T Lymphocytes in Treating Cytomegalovirus Infection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: Not specified
Trial IDs: H-2866, NCI-2012-01428, ARM, H-2996 ARM, NCT01664645

Donor Multi-virus-Specific Cytotoxic T Lymphocytes in Treating Epstein-Barr Virus, Cytomegalovirus, Adenovirus, Human Herpes Virus 6, and BK Virus Infections in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: Not specified
Trial IDs: H-29966, NCI-2012-02979, ARMS, H-29966 ARM, NCT01570283

Donor Multivirus-Specific T Cells in Treating Patients with Persistent or Recurrent Viral Infections after Donor Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: H-33903, NCI-2014-00896, CHARM, NCT02108522

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Inherited Metabolic Disorders
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 00015791, NCI-2011-03853, NCT01372228

Donor Peripheral Stem Cell Transplant in Treating Patients With Severe Autoimmune Diseases
Phase: Phase II
Type: Treatment
Age: 18 to 69
Trial IDs: Pro00010324, NCI-2013-01245, NCT00849745

Donor Regulatory T Lymphocytes in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 18 to 70
Trial IDs: 17263, NCI-2014-01426, MCC-17263, NCT01795573

Donor Stem Cell Transplant after Busulfan and Fludarabine Phosphate with or without Anti-thymocyte Globulin in Treating Patients with Inherited Metabolic Disorders, Severe Osteoporosis, or Rett Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 17263, NCI-2014-01426, MCC-17263, NCT01795573

Effect of Radiation on Bone in Patients with Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 14-208, NCI-2015-00893, NCT02532395

Efficacy and Safety of Ferritox® in Patients With Sickle Cell Disease or Other Anemias
Phase: Phase IV
Type: Treatment
Age: 2 and over
Trial IDs: LA38-0411, NCI-2014-01229, NCT02041299

Efficacy and Safety Study of CS148 in Stem Cell Transplant Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: CS148X2201, NCI-2015-00634, NCT02268526

Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: MITO 02-03, NCI-2012-00422, NCT00801086

Eligibility Screening and Research Sample Collection in Determining Patient Eligibility to Participate in Clinical Trials
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Health services research
Age: Not specified
Trial IDs: 01-C-0129, NCI-2013-02022, 011209, 01-C-0129
M, NCT0026754

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15677, NCI-2015-01298, 2015-000343-30, 1B5-2MC-JGDI, NCT02455943

Acupuncture in Treating Chemotherapy-Induced Neuropathy in Cancer Survivors
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 and over
Trial IDs: 2013-0930, NCI-2014-01466, NCT02168894